Based on results from other ongoing trials of epacadostat combined with PD-(L)1 inhibition, epacadostat 100 mg BID showed a favorable tolerability profile and preliminary antitumor activity, and this dose was chosen for Phase III combination studies in several tumor types. The gene discussed is CD274; the disease is neoplasm.